4D Molecular Therapeutics, Inc. — Director's Dealing 2021

Jun 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 4D Molecular Therapeutics Inc. (FDMT)
CIK: 0001650648
Period of Report: 2021-06-07

Reporting Person: Zimmermann Carolyne (Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-07	Stock Option (Right to Buy)	$26.83	A	60000	Acquired	2031-06-06	Common Stock (60000)	Direct

Footnotes

F1: The stock option will vest with respect to 25% of the total number of the underlying shares on June 7, 2022, and the remaining shares will vest in equal monthly installments over the following three-year period, such that the stock option will be fully vested on June 7, 2025, subject to the Reporting Person continuing to be a service provider to Issuer through each vesting date.